MRI anatomy of the rectum: key concepts important for rectal cancer staging and treatment planning
Insights into Imaging volume 14, Article number: 13 (2023)
A good understanding of the MRI anatomy of the rectum and its surroundings is pivotal to ensure high-quality diagnostic evaluation and reporting of rectal cancer. With this pictorial review, we aim to provide an image-based overview of key anatomical concepts essential for treatment planning, response evaluation and post-operative assessment. These concepts include the cross-sectional anatomy of the rectal wall in relation to T-staging; differences in staging and treatment between anal and rectal cancer; landmarks used to define the upper and lower boundaries of the rectum; the anatomy of the pelvic floor and anal canal, the mesorectal fascia, peritoneum and peritoneal reflection; and guides to help discern different pelvic lymph node stations on MRI to properly stage regional and non-regional rectal lymph node metastases. Finally, this review will highlight key aspects of post-treatment anatomy, including the assessment of radiation-induced changes and the evaluation of the post-operative pelvis after different surgical resection and reconstruction techniques.
MRI plays a key role in the staging and treatment stratification of rectal cancer.
Understanding rectal and pelvic MRI anatomy is pivotal for high-quality reporting.
This review addresses key anatomy concepts for staging, treatment planning, and follow-up.
Magnetic resonance imaging (MRI) plays a key role in the staging and treatment stratification of patients with rectal cancer. High-resolution MRI can accurately assess tumour infiltration in and beyond different layers of the bowel wall, as well as invasion into important anatomical structures such as the mesorectal fascia (MRF), peritoneum, and surrounding pelvic organs [1,2,3,4,5,6]. By doing so, MRI provides crucial information to determine the risk profile of each individual patient to help decide who will benefit from neoadjuvant (chemo)radiotherapy (CRT) [6, 7]. The MRI findings can guide the surgical approach and help the radiation oncologist to accurately define his radiation target volumes. MRI has also been widely adopted as a valuable tool to assess response after neoadjuvant treatment. The findings of restaging MRI can help the surgeon to fine tune his surgical approach and aid in the selection of patients with a (near) complete response who may be candidates for organ-preserving treatment alternatives such as watch-and-wait (W&W) [2, 8,9,10]. MRI is also valuable to help determine the local extent of disease in case of a suspected pelvic recurrence [11,12,13]. In all these scenarios, a good understanding of the MRI anatomy of the rectum and its surroundings is pivotal to ensure high-quality diagnostic evaluation and reporting. This pictorial review will discuss key anatomical concepts essential for staging, treatment planning, and post-treatment assessment on MRI.
The rectal wall and T-staging
Anatomically, the rectal wall comprises three main layers: an inner mucosal layer, the underlying submucosa, and an outer muscular layer, the muscularis propria. The depth of invasion into and beyond these layers determines the tumour stage (T-stage) in rectal cancer, as outlined in Table 1 [4, 15, 26]. T-stage is one of the prognostic risk factor used in clinical guidelines to determine the most appropriate treatment strategy. Tumours that remain limited to the submucosa (T1) or that extend into but not beyond the muscularis propria (T2) are typically considered clinically as early-stage tumours that may be managed with surgery only (total mesorectal excision) or even local endoscopic excision [4, 14, 15], provided that there are no other adverse features such as lymph node metastases. Tumours that grow beyond the muscularis propria into the mesorectal fat, i.e. tumours with extramural invasion, are classified as T3. These can range from low-risk tumours with limited extramural invasion (T3a and T3b) to more high-risk tumours with more extensive extramural invasion (T3c and T3d), or T3 tumours that invade the MRF (see Fig. 1 and also section on mesorectum and mesorectal fascia below) [4, 15]. These high-risk tumours typically require neoadjuvant (chemo)radiotherapy .
It is important to realise that on a routine T2-weighted MRI, the rectal wall typically has a two-layered instead of three-layered appearance with a total thickness of only 2–3 mm . The mucosa and submucosa are in most cases indistinguishable and seen as a single intermediate signal layer surrounded by a second T2-hypointense layer that represents the muscularis propria (Fig. 2A). The mucosa and submucosa can be recognised as separate layers on MRI in the presence of submucosal oedema (for example, as a result of radiation therapy). In these cases, the submucosa is visualised as a high signal middle layer between the mucosa and muscularis propria (Fig. 2B). The limited visibility of the separate layers of the bowel wall is one of the main reasons why MRI is generally unable to discern T1 from T2 tumours and why these are often reported together on MRI as stage cT1-2 (Fig. 2D), as is also the case in the structured reporting and staging template published by the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) .
Upper and lower boundaries of the rectum
Upper boundary: the sigmoid take-off
Various definitions and landmarks have been used throughout the years to determine the upper boundary of the rectum, including the sacral promontory, third sacral vertebra, anterior peritoneal reflection, and distance measurements from the anorectal junction or anal verge [4, 17, 18]. The main clinical significance of defining the upper limit of the rectum during tumour staging is to differentiate rectal tumours from tumours arising in the sigmoid colon. Patients with sigmoid cancers are primarily managed with upfront surgery, while patients with rectal cancers usually undergo differentiated treatments varying from surgery only in low-risk tumours to short or long course neoadjuvant (chemo)radiotherapy in intermediate and high-risk tumours [4, 14, 15]. Recently, an international multidisciplinary expert consensus panel agreed on the “sigmoid take-off” (STO) as the preferred landmark to define the boundary between the rectum and sigmoid colon on imaging . The STO marks the junction between the mesorectum and sigmoid mesocolon and can be recognised on sagittal views as the point from which the sigmoid sweeps horizontally (away from the sacrum) and on axial views as the point from which the sigmoid projects ventrally (Fig. 3).
Recognising the STO on imaging requires some training. It may be challenging due to variations in the anatomical course of the rectosigmoid related to the degree of luminal distension (by tumour or gas), mass effect from adjacent organs, pelvic floor insufficiency, or surgical history. The inconsistent angulation of axial imaging planes on MRI may also be a challenging factor [20, 21]. Nevertheless, the STO is generally considered an intuitive landmark. In 2019, the Dutch guidelines on colorectal cancer were one of the first to adopt the STO as a formal landmark to discern rectal from sigmoid cancer, defining rectal cancer as any tumour with a lower boundary starting below the level of the STO and sigmoid cancer as any tumour situated entirely above the level of the STO . Reports from the Netherlands have shown that this new definition can impact treatment planning (e.g. the choice of surgery or neoadjuvant treatment) compared to traditional approaches with no standardised definitions in up to 19% of patients with tumours near the rectosigmoid junction .
Lower boundary: anorectal junction and anal verge
How to define the lower boundary of the rectum also remains a somewhat controversial topic. A commonly reported anatomical landmark is the dentate line, which marks the transition line between the columnar rectal mucosa and squamous anal mucosa. The dentate line is, however, not recognisable on imaging. Landmarks more commonly used in clinical practice are the anorectal junction and the anal verge (Fig. 4). The anorectal junction is commonly used by surgeons to separate the rectum from the anal canal. It is typically located 1–2 cm proximal to the dentate line and is palpable upon digital rectal examination at the level of the muscular anorectal ring, which includes the puborectal sling and the upper portions of the external anal sphincter [22, 23]. The anorectal junction can also be visualised with high reproducibility on MRI and is commonly used as a landmark from which to measure the height of the tumour, e.g. “tumour starts at … cm from the anorectal junction”. As a rule of thumb, on MRI the anorectal junction is situated at the level of an imaginary line between the lower margin of the sacral and pubic bone on sagittal MRI (Figs. 3A and 4) or on coronal plane as a line across the upper boundary of the puborectal sling. The anal verge marks the transition between the epithelium of the anal canal and the perianal skin. It is used by some radiologists instead of the anorectal junction as a landmark on MRI (Fig. 4) and is also typically used as a landmark during endoscopic examinations. The first ± 5 cm of perianal skin caudal to the anal verge is referred to as the anal margin. From a clinical point of view, defining the tumour's location (or height) is relevant because this information helps the surgeon determine whether or not there is sufficient margin between the lower border of the tumour and the anal canal to perform a low anterior resection and create an anastomosis. Ultimately this decision will be informed by a combination of digital rectal examination, endoscopy and MRI.
The anal canal and pelvic floor
A good quality staging report of any low rectal tumour should include an accurate description of the relation of the tumour to the different layers of the anal canal and pelvic floor. The presence and extent of invasion into these respective structures define the surgical resection strategy and help the surgeon decide whether, for example, an intersphincteric resection could still be feasible or if the patient requires a routine or even extralevator abdominoperineal resection (APR; see also section on surgical techniques and post-surgical anatomy below). It is also important information for radiation oncologists to guide target volume delineation. To properly assess invasion into the anal canal and pelvic floor (Fig. 5), it is vital to include in the MRI protocol for low rectal tumours a high-resolution T2-weighted plane that is acquired parallel to the anal canal.
As shown in Fig. 5, the anal sphincter consists of three main layers. The inner layer, the ‘internal sphincter’, is a thickened continuation of the inner circular muscle of the rectum. The external sphincter is comprised of striated muscle and forms the outer part of the anal sphincter. It is continuous with the striated puborectalis and levator ani muscles at the upper end [24, 25]. Together with the iliococcygeus and pubococcygeus muscles, the puborectal and levator ani muscles form the “pelvic floor” [24, 25]. On MRI, the internal and external sphincter and pelvic floor muscles appear hypointense on T2W sequences, while the intersphincteric plane is typically hyperintense.
Note: impact of anal sphincter and pelvic floor invasion on T-stage categorisation
With respect to T-stage categorisation of low rectal cancers, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) Tumour Nodes Metastases (TNM) staging system does not clearly define how to take invasion of different layers of the anal sphincter and pelvic floor into account. In 2021, a multidisciplinary expert consensus panel of radiologists, surgeons, radiation oncologists, and pathologists discussed this issue. They proposed that the clinical T-stage (cT-stage) on MRI—like the pT-stage in pathology—should primarily be informed by the extent of tumour invasion at the level of the rectum. Involvement of the external sphincter, puborectalis, and/or levator ani muscles should be classified as cT4b disease as this entails skeletal muscle invasion. Invasion of the internal sphincter and intersphincteric plane by itself should not affect the cT-stage categorisation but their invasion should always be additionally described .
Note: anal versus rectal cancer
It is important to note that the definition of rectal versus anal cancer primarily depends on the underlying tumour histology. Rectal cancers arise from large bowel mucosa and are typically adenocarcinomas, while anal cancers arise from squamous or transitional epithelium and are typically squamous cell carcinomas (SCC). Rectal adenocarcinomas may extend into the anal canal or may even be located for the majority within the anal canal. Conversely, anal squamous cell carcinomas may extend above the level of the anorectal junction and involve the rectum. SCCs originating primarily from the rectum and adenocarcinomas of the anal canal have also been reported but are rare, representing only a small minority of cases [27, 28]. Since the histological tumour type denotes important differences in tumour biology with subsequent differences in treatment responses, it is typically the main factor that guides clinical decision making, regardless of anatomical location and extension. Main differences in staging and treatment between rectal cancer and anal cancer are summarised in Table 2.
The mesorectal compartment, mesorectal fascia and peritoneum
Mesorectum and mesorectal fascia
The rectum and surrounding mesorectal fat (the mesorectum) are enveloped by the mesorectal fascia (MRF) and are fixed to the sacrum by the presacral fascia of Waldeyer. The MRF is a thin fibrous structure that comprises the anticipated resection plane when performing a total mesorectal excision (TME). The term MRF is sometimes used interchangeably with the term circumferential resection margin (CRM), which is incorrect. The MRF is an anatomical structure, whereas the CRM is a more technical term indicating the margin a surgeon creates when performing his resection (and the margin pathologists report when describing the smallest distance between the tumour and the outer plane of the resected specimen). Therefore, radiologists should avoid using CRM but rather describe the tumour in relation to the MRF . The MRF should be considered as involved when the tumour invades the MRF directly or the margin between the tumour and MRI is ≤ 1 mm (Fig. 1) . In a recent expert consensus guide it was proposed that these criteria apply to the primary tumour, but also to EMVI or any irregular nodes or tumour deposits that invade or are within 1 mm from the MRF . On T2-weighted MRI, the MRF is easily recognised as a thin hypointense line surrounding the mesorectum (Fig. 6A). The mesorectal fat is thinner on the anterior side than on the lateral and posterior sides. Therefore, a close relation exists between the anterior rectal wall and the prostate and seminal vesicles in men and the vagina and cervix in women. The mesorectal compartment tapers towards the distal end (Fig. 6B). Consequently, tumours located in the distal rectum are at higher risk for MRF involvement. In case of suspected MRF involvement, patients are typically stratified for neoadjuvant treatment aiming to induce tumour downsizing, increase the chance of a tumour free resection margin and reduce the chance of a local recurrence.
Peritoneum and peritoneal reflection
The anterior peritoneal reflection is a thin layer of visceral peritoneum that separates the rectum’s extra- and intraperitoneal parts. On MRI, it typically has a V-shaped appearance (or gull-wing appearance, therefore sometimes referred to as the “seagull sign”). In the sagittal plane, it extends from the top of the seminal vesicles in men and from the level of the cul-de-sac (Douglas’ pouch) in women, as shown in Fig. 7 .
It is important to realise that the MRF envelopes the entire circumference of the mesorectal compartment only below the level of the anterior peritoneal reflection. Above this level, the MRF ascends dorsolaterally to cover the mesorectum only on the lateral and dorsal part. Above the peritoneal reflection, the anterior mesorectum is covered by peritoneum, as illustrated in Fig. 8. The MRF and peritoneum are thus two separate anatomical structures, and separate recognition of their respective invasion is important for cT-staging. While invasion into the MRF constitutes cT3 disease (cT3 MRF+), invasion of the peritoneal covering at any location, including the anterior peritoneal reflection, constitutes cT4a disease. When MRF invasion and peritoneal invasion co-occur, this entails cT4a MRF+ disease, as shown in Fig. 8 .
Extramesorectal organs and ‘structures’
When staging locally advanced tumours, it is essential to clearly describe any tumour invasion into organs or structures in the pelvis situated outside the mesorectal compartment. This information is important for surgical and radiotherapy planning, but also impacts the cT-stage classification. Note that the AJCC/UICC TNM staging system does not include a clear description of what is covered by the umbrella term “structures” when classifying T4b disease as “any tumour with invasion of another organ or structure”. The lack of a clear definition for cT4b disease was identified as an important staging controversy by a recently published survey on the radiological application of the TNM staging system for rectal cancer [15, 26]. Based on the outcomes of this survey, a multidisciplinary panel of experts agreed that from a treatment point of view, cT4b disease should include any tumour with direct invasion of either another organ or any anatomical compartment or structure outside the mesorectum on MRI that would require adaptation of the standard surgical resection plane, including (see also T-stage definitions in Table 1):
Pelvic organs (uterus, ovaries, vagina, prostate, seminal vesicles, bladder)
striated/skeletal muscle (incl. external anal sphincter, puborectalis, and levator ani, obturator, piriformis, and ischiococcygeus)
ureters and urethra
sciatic or sacral nerves
any vessel outside the mesorectal compartment
any loop of small or large bowel in the pelvis (separate from the primary site from which the tumour originates)
any fat in an anatomical compartment outside the mesorectal compartment (i.e. obturator, para-iliac, or ischiorectal space)
Different examples of cT4b invasion are provided in Fig. 9. Note that invasion of the peritoneum alone—even though situated outside the mesorectal compartment—is not considered cT4b disease but is classified separately as cT4a as detailed above.
Blood supply, lymphatic drainage and lymph node stations
The arterial supply of the rectum consists of the superior, middle and inferior rectal arteries. The superior rectal artery is the terminal branch of the inferior mesenteric artery and constitutes the main feeding artery of the rectum. On axial T2-weighted MR images, the superior rectal artery and its branches can be detected as low-intensity, tubular structures in the presacral region (Fig. 10A), with the superior rectal vein running parallel to it (typically on the left dorsal side). The distal part of the rectum receives additional blood supply from the middle rectal artery, an inconsistent branch from the internal iliac artery. The inferior rectal artery originates from the pudendal artery, a branch of the internal iliac artery. It is situated below the pelvic floor muscles and contributes very little to the blood supply of the rectum; it mainly supplies the distal part of the anal canal. Anastomoses between the lateral and median sacral veins, which accompany the corresponding arteries that arise from the dorsal side of the aorta just above the bifurcation, together form the so-called presacral venous plexus behind Waldeyer’s fascia (Fig. 10B, C). The presacral venous plexus can bleed profusely if accidentally injured during rectal surgery.
Note that the upper two-thirds of the rectum are drained by the superior rectal vein, which empties into the portal system via the inferior mesenteric vein. The venous drainage of the lower third of the rectum runs via the middle and inferior rectal veins, which drain into the systemic venous circulation via the internal iliac veins . This explains why lower rectal tumours have a relatively higher incidence of pulmonary metastases (without hepatic metastases) than higher tumours .
Small mesorectal vasculature and extramural vascular invasion (EMVI)
In addition to the larger arteries and veins described in the previous section, there are also numerous unnamed smaller vessels that radiate outwards from the edge of the muscularis propria into the perirectal fat. These smaller vessels can be visualised as small serpiginous branches, as illustrated in Fig. 11A. Extramural vascular invasion (EMVI) can occur in tumours that grow beyond the muscularis propria (≥ T3) and is defined as the extension of tumour within these small perirectal blood vessels . It is a known adverse prognostic risk factor associated with recurrent disease, metastases and impaired overall survival . On MRI, EMVI can be visualised as direct tumour signal extending into a blood vessel, with or without expansion of the vessel or infiltration of the vessels borders (Fig. 11B).
Lymphatic drainage and lymph node stations
The main lymphatic drainage of the rectum follows the superior rectal artery and vein towards the inferior mesenteric vein. Most of the lymph nodes in the mesorectum are situated along these vessels in the posterior and lateral parts of the mesorectum . Criteria used in current guidelines to characterise mesorectal lymph nodes as malignant are based on a combination of size and morphology. Nodes are considered as suspicious for N+ when ≥ 9 mm, 5–8 mm with two morphologically suspicious features, or < 5 mm with three suspicious features. Morphologic criteria suspicious for malignancy are an indistinct border, round (rather than oval) shape, and heterogeneous signal. Mucinous lymph nodes (in mucinous tumours) are always considered as cN+ .
Tumours below the anterior peritoneal reflection (in the distal and middle parts of the rectum) follow an additional lymphatic drainage route alongside the middle rectal artery and vein towards the so-called lateral nodal stations situated outside the mesorectum. These lateral nodes include the internal iliac, obturator and external iliac nodes [35,36,37]. Note that in some publications (mainly from Japanese studies), the common iliac nodes are also referred to as lateral nodes [38, 39]. Pathologic lymph nodes in the obturator and internal iliac areas are—despite their extra-mesorectal location—still considered “regional” disease and are mainly associated with an increased risk for lateral local recurrence [35, 37, 40]. Though included as regional nodes in the N-stage category of the TNM staging system, pathologic obturator and internal iliac nodes need to be reported separately as they will not be removed with standard TME surgery and require targeted radiotherapy and/or lateral nodal dissection to avoid lateral nodal recurrences. Radiologists thus need to alert the radiation oncologist and surgeon of any N+ nodes in these regions to guide target delineation and surgical planning. Data from the Lateral Nodal Study Consortium indicate a short axis diameter of ≥ 7 mm as a criterion to diagnose N+ nodes in the obturator and internal iliac regions; unlike in mesorectal lymph nodes, morphologic criteria are not of added benefit for lateral nodal staging [36, 37]. Nodal metastases along the external and common iliac vessels are much less common and are mainly associated with an increased risk for distant metastases . Therefore, these nodes are considered non-regional disease and included in the M-stage classification. Pathologic inguinal nodes also constitute M+ disease, although—like in anal cancer—they may still be considered regional nodal metastases in tumours extending into (or situated primarily in) the distal anal canal, considering the regional lymphatic drainage route from the anal canal towards the superficial inguinal nodes . Table 3 provides an overview of the different lymph node stations and variations in terminology used to describe them, which can sometimes be a source of confusion. Clear guidelines describing how to discern the different lymph node compartments on imaging have also been lacking, which has contributed to substantial variation in the radiological reporting of these nodes . Figure 12 details how the various mesorectal and lateral lymph node stations can be discerned on MRI using surgical definitions derived from a publication by Ogura et al. from 2019 . These definitions can serve as a roadmap for radiologists to help improve consistency in nodal reporting.
Anatomical considerations after neoadjuvant treatment
Commonly used neoadjuvant treatment regimens include a short course of radiotherapy (5 × 5 Gy) prior to TME for intermediate-risk tumours (typically cT3cd and/or cN+) and a long course of combined chemoradiotherapy for locally advanced tumours (typically cT3 MRF+, cT4 and/or cN+). The latter is intended to induce tumour downsizing and downstaging to enhance the chance of radical surgical resection [4, 14]. In response to these treatments, rectal tumours typically decrease in size while undergoing a fibrotic transformation. When tumours become fibrotic, their T2-weighted signal drops from intermediate (lower than fat, higher than muscle) to markedly hypointense, as illustrated in Fig. 13. When the tumour bed has become predominantly fibrotic, it is difficult to discern on T2-weighted MRI whether we are dealing with only fibrosis or fibrosis still containing nests of viable residual tumour. This greatly limits the performance of standard MRI in the restaging setting, resulting in a suboptimal performance for ycT-staging, but also for and assessment of yEMVI and yMRF involvement [41,42,43]. Diffusion-weighted imaging (DWI) highlights hypercellular tissues and can enhance the performance of MRI to detect areas of vital (hypercellular) residual tumour within the fibrotically changed tumour bed. DWI is therefore now recommended to be included in the standard MRI protocol for restaging after neoadjuvant treatment, in specific for the differentiation between complete responders (who may be candidates for organ preservation) and patients with residual tumour . Evidence on the benefit of DWI for further restaging (e.g. yEMVI, yMRF, yN) is limited . In addition, specific imaging patterns and criteria have been described in the restaging setting, such as the MRI tumour regression grade (mrTRG) to grade the degree of fibrosis versus residual tumour, or patterns to help assess the risk of persistent MRF invasion in case of fibrosis after CRT. An in-depth discussion of these patterns, the pearls and pitfalls of DWI, and the role of MRI for organ preservation is, however, outside the scope of this anatomy-focused review. We therefore kindly refer the interested reader to previous publications on these topics [41, 44,45,46,47].
Surgical techniques and post-surgical anatomy
MRI is not routinely performed during the follow-up of patients after curative resection. However, it is valuable (as a second-line modality) to help detect and evaluate the extent of disease in patients with suspected pelvic recurrence. In these cases, a proper understanding of post-surgical anatomy is crucial. A schematic overview of some of the most commonly used surgical techniques, including corresponding post-surgical MR images, is provided in Fig. 14.
Local excision is a general term used to describe minimally invasive endoscopic techniques used to resect non-cancerous polyps and early-T-stage cancers (T1 and some good prognostic T2 tumours). Endoscopic mucosal resection (EMR) and endoscopic submucosal resection (ESD) are superficial excision techniques, while transanal minimally invasive surgery (TAMIS) or transanal endoscopic microsurgery (TEM; a similar but older technique) allow full-thickness resection of the rectal wall up to the mesorectal fat. After EMR or ESD, MRI can show a subtle focal fibrotic scar at the excision site, although no abnormalities are observed in many cases. After TEM/TAMIS, MRI typically shows a defect in the rectal wall surrounded by fibrosis (Fig. 14A). Early post-operative changes may also include inflammatory changes and oedema, which can give the former tumour bed and scar a very irregular appearance that should not be mistaken for recurrence . After a more extended follow-up period, these inflammatory changes gradually disappear.
Total mesorectal excision (TME)
TME remains the standard surgical procedure for rectal cancer. With TME, the entire mesorectal compartment is removed alongside the MRF. In upper rectal or rectosigmoid junction tumours, a partial mesorectal excision (PME) can be performed where part of the distal-middle rectum and mesorectum are left in situ. TME is an umbrella term that covers different surgical resection techniques, including a low anterior resection (LAR), and an abdominoperineal resection (APR). LAR is typically performed in middle-upper tumours. The anal canal is left in situ, and there is sufficient margin to create an anastomosis (typically a ‘side-to-end’ anastomosis) between the remaining distal rectum and sigmoid colon (Fig. 14B). APR is indicated for low rectal tumours that approximate or involve the anal canal. With an APR, the rectum and anal canal are resected en bloc, and the patient receives a permanent colostomy (Fig. 14C). Variations to the standard APR include the intersphincteric approach, where the external sphincter is spared, and the extralevator APR, a more extensive procedure for tumours invading the pelvic floor, including resection of the levator ani muscles.
After APR, the pelvic floor and perineum can be closed primarily, with the use of a mesh, or with plastic reconstructive techniques such as the vertical or oblique rectus abdominis myocutaneous flaps (VRAM/ORAM, see example in Fig. 14C), or gluteal flaps. Additionally, the greater omentum (omentoplasty) can be used to fill the pelvis. Early post-operative T2-weighted images of the muscular portion of a musculocutaneous flap show (low) muscle signal intensity. Over time, denervation results in muscular atrophy, and eventually, the muscular part of the flap is replaced by fat with a corresponding increase in signal (see Fig. 14C) . An omentoplasty also shows a high signal on T2-weighted MRI as it primarily contains fat. Some small lymph nodes may be present within the omentoplasty that will typically be easy to recognise as benign (smooth, oval, homogeneous with fatty hilum) . Other common findings after TME, especially in patients who have experienced post-operative anastomotic leakage, include the formation of extensive post-operative fibrosis and sometimes chronic presacral sinus formation . An example of a case with extensive post-operative fibrosis is given in Fig. 15. These fibrotic changes should not be mistaken for residual or recurrent tumour.
With this pictorial review, we aimed to provide an image-based overview of key anatomical concepts essential for treatment planning, response evaluation and post-operative assessment on MRI. A good understanding of the MRI anatomy of the rectum and its surroundings is pivotal to ensure high-quality diagnostic evaluation and reporting for primary staging and treatment planning of patients with rectal cancer. Knowing the spectrum of normal changes in anatomy and morphology of the rectal wall following (chemo)radiotherapy and key surgical concepts are vital to understanding how to interpret MRI following neoadjuvant or curative surgical treatment.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
American Joint Committee on Cancer
Circumferential resection margin
Endoscopic mucosal resection
Endoscopic submucosal resection
European Society of Gastrointestinal and Abdominal Radiology
Low anterior resection
Magnetic resonance imaging
Partial mesorectal excision
Squamous cell carcinoma
Transanal minimally invasive surgery
Transanal endoscopic microsurgery
Total mesorectal excision
Union for International Cancer Control
MERCURY Study Group (2007) Extramural depth of tumour invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 243(1):132–139
Beets-Tan RGH, Lambregts DMJ, Maas M et al (2018) Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 28(4):1465–1575
Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW (2003) Williams GT preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90(3):355–364
Glynne-Jones R, Wyrwicz L, Tiret E et al (2017) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:22–40
Valentini V, Aristei C, Glimelius B et al (2009) Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2). Radiother Oncol 92(2):148–163
Lahaye MJ, Engelen SM, Nelemans PJ et al (2005) Imaging for predicting the risk factors–the circumferential resection margin and nodal disease-of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 26(4):259–268
Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J (2004) Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology 232(3):773–783
Lambregts DM, Vandecaveye V, Barbaro B, et al. (2011) Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 18(8):2224–2231
Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29(35):4633–4640
Brown PJ, Hyland R, Quyn AJ, et al. (2019) Current concepts in imaging for local staging of advanced rectal cancer. Clin Radiol 74(8):623–636
Gollub MJ, Das JP, Bates DDB, et al. (2021) Rectal cancer with complete endoscopic response after neoadjuvant therapy: What is the meaning of a positive MRI? Eur Radiol 31(7):4731–4738
Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, Petkovska I, Gollub MJ (2019) MRI of rectal cancer: tumour staging, imaging techniques, and management. Radiographics 39(2):367–387
Hoeffel C, Arrivé L, Mourra N, Azizi L, Lewin M, Tubiana JM (2006) Anatomic and pathologic findings at external phased-array pelvic MR imaging after surgery for anorectal disease. Radiographics 26(5):1391–1407
Federatie Medische Specialisten (2022) Richtlijn colorectaal carcinoom (2019 update). Available at: https://richtlijnendatabase.nl/richtlijn/colorectaal_carcinoom_crc/startpagina_-_crc.html Accessed June 06, 2022
Jessup MJ, Goldberg RM, Asare EA et al (2017) CP Colon and Rectum. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK et al (eds) AJCC cancer staging manual, 8th edn. Springer, Berlin, pp 251–273
Bennett AE (2008) Correlative anatomy of the anus and rectum. Semin Ultrasound CT MR 29(6):400–408. https://doi.org/10.1053/j.sult.2008.10.007
Wittekind C, Brierly JD, Lee AWM et al (2019) CP. Explanatory notes specific anatomical sites. In: Wittekind C, Brierly JD, Lee AWM et al (eds) TNM supplement A commentary uniform use. Wiley-Liss, New York, pp 54–85
D’Souza N, Balyasnikova S, Tudyka V et al (2018) Variation in landmarks for the rectum: an MRI study. Colorectal Dis 20(10):O304–O309
Dsouza N, de Neree Tot Babberich MPM, d’Hoore A et al (2019) Definition of the rectum: an international, expert-based Delphi consensus. Ann Surg 270(6):955–959
Bogveradze N, Lambregts DMJ, Khababi N et al (2021) The sigmoid take-off as a landmark to distinguish rectal from sigmoid tumours on MRI: reproducibility, pitfalls and potential impact on treatment stratification. Eur J Surg Oncol 20:S0748-7983. https://doi.org/10.1016/j.ejso.2021.09.009
Hazen SJA, Sluckin TC, Horsthuis K et al (2022) Evaluation of the implementation of the sigmoid take-off landmark in the Netherlands. Colorectal Dis 24(3):292–307. https://doi.org/10.1111/codi.16005
Jorge JMN, Habr-Gama A (2014) Anatomy and embryology of the colon, rectum and anus. In: Beck DE, Nasseri Y, Hull TL et al (eds) The ASCRS manual of colon and rectal surgery, 2nd edn. Springer, Berlin, pp 1–27
Shank B, Enker WE, Flam MS (2003) Gross and microscopic anatomy. In: Holland-Frei Cancer Medicine, 6th edn. BC Decker, Hamilton, ON. https://www.ncbi.nlm.nih.gov/books/NBK13638/.
Lee JM, Kim NK (2018) Essential anatomy of the anorectum for colorectal surgeons focused on the gross anatomy and histologic findings. Ann Coloproctol 34(2):59–71. https://doi.org/10.3393/ac.2017.12.15
Stoker J (2009) Anorectal and pelvic floor anatomy. Best Pract Res Clin Gastroenterol 23(4):463–475. https://doi.org/10.1016/j.bpg.2009.04.008
Lambregts DMJ, Bogveradze N, Blomqvist LK et al (2022) Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol. https://doi.org/10.1007/s00330-022-08591-z
van Rees JM, Elferink MAG, Tanis PJ et al (2021) The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: a population-based study between 1989 and 2018. Eur J Cancer 152:183–192
Lukovic J, Kim JJ, Krzyzanowska M et al (2020) Anal adenocarcinoma: a rare malignancy in need of multidisciplinary management. JCO Oncol Pract 16(10):635–640
Glimelius B, Beets-Tan R, Blomqvist L et al (2011) Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol 29(16):2142–2143
Gollub MJ, Maas M, Weiser M et al (2013) Recognition of the anterior peritoneal reflection at rectal MRI. AJR Am J Roentgenol 200:97–101
Sakorafas GH, Zouros E, Peros G (2006) Applied vascular anatomy of the colon and rectum: clinical implications for the surgical oncologist. Surg Oncol 15(4):243–255
Smith NJ, Shihab O, Arnaout A, Swift RI, Brown G (2008) MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol 191(5):1517–1522
Tan JJ, Carten RV, Babiker A, Abulafi M, Lord AC, Brown G (2021) Prognostic importance of MRI-detected extramural venous invasion in rectal cancer: a literature review and systematic meta-analysis. Int J Radiat Oncol Biol Phys 111(2):385–394
Dworak O (1991) Morphology of lymph nodes in the resected rectum of patients with rectal carcinoma. Pathol Res Pract 187(8):1020–1024
Schaap DP, Boogerd LSF, Konishi T et al (2021) Rectal cancer lateral lymph nodes: multicentre study of the impact of obturator and internal iliac nodes on oncological outcomes. Br J Surg 108(2):205–213
Ogura A, Konishi T, Cunningham C et al (2019) Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol 37(1):33–43
Ogura A, Konishi T, Beets GL et al (2019) Lateral node study consortium. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy. JAMA Surg 154(9):192172
Yagi R, Shimada Y, Kameyama H et al (2016) Clinical significance of extramural tumor deposits in the lateral pelvic lymph node area in low rectal cancer: a retrospective study at two institutions. Ann Surg Oncol 23(Suppl 4):552–558
Akiyoshi T, Watanabe T, Miyata S et al (2012) Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg 255(6):1129–1134
Sluckin TC, Couwenberg AM, Lambregts DMJ et al (2022) Lateral lymph nodes in rectal cancer: Do we all think the same? A review of multidisciplinary obstacles and treatment recommendations. Clin Colorectal Cancer S1533–0028(22):00025–00031. https://doi.org/10.1016/j.clcc.2022.02.002
Lambregts DMJ, Boellaard TN, Beets-Tan RGH (2019) Response evaluation after neoadjuvant treatment for rectal cancer using modern MR imaging: a pictorial review. Insights Imaging 10(1):15
Barbaro B, Vitale R, Leccisotti L et al (2010) Restaging locally advanced rectal cancer with MR imaging after chemoradiation therapy. Radiographics 30(3):699–716
Van der Paardt MP, Zagers MB, Beets-Tan RG et al (2013) Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 269(1):101–112
Schurink NW, Lambregts DMJ, Beets-Tan RGH (2019) Diffusion-weighted imaging in rectal cancer: current applications and future perspectives. Br J Radiol 92(1096):20180655
Vliegen RF, Beets GL, Lammering G et al (2008) Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology 246(2):454–462
Siddiqui MR, Gormly KL, Bhoday J et al (2016) Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). Clin Radiol 71(9):854–862
van der Valk MJM, Hilling DE, Bastiaannet E et al (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch and Wait Database (IWWD): an international multicentre registry study. Lancet 391(10139):2537–2545
Hupkens BJP, Maas M, Martens MH et al (2017) MRI surveillance for the detection of local recurrence in rectal cancer after transanal endoscopic microsurgery. Eur Radiol 27(12):4960–4969
Sagebiel TL, Faria SC, Balachandran A et al (2011) Pelvic reconstruction with omental and VRAM flaps: anatomy, surgical technique, normal postoperative findings, and complications. Radiographics 31(7):2005–2019
Borstlap WAA, Westerduin E, Aukema TS et al (2017) Anastomotic leakage and chronic presacral sinus formation after low anterior resection: results from a large cross-sectional study. Ann Surg 266(5):870–877
Ethics approval and consent to participate
Consent for publication
The images included in this manuscript cannot be traced to individual persons.
Regina Beets-Tan is a member of the Insights into Imaging Advisory Editorial Board. She has not taken part in the review or selection process of this article. The authors remaining declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bogveradze, N., Snaebjornsson, P., Grotenhuis, B.A. et al. MRI anatomy of the rectum: key concepts important for rectal cancer staging and treatment planning. Insights Imaging 14, 13 (2023). https://doi.org/10.1186/s13244-022-01348-8
- Magnetic resonance imaging
- Rectal cancer
- Treatment planning